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ABSTRACT
We determined the prevalence of self-reported late-effects in survivors of autologous hematopoietic cell
transplantation (HCT) for Hodgkin lymphoma (HL, n  92) and non-Hodgkin lymphoma (NHL, n  184)
using a 255-item questionnaire and compared them to 319 sibling controls in the Bone Marrow Transplant
Survivor Study. Median age at HCT was 39 years (range: 13-69) and median posttransplant follow-up was 6
years (range: 2-17). Median age at survey was 46 years (range: 21-73) for survivors and 44 years (range: 19-79)
for siblings. Compared to siblings, HCT survivors reported a significantly higher frequency of cataracts, dry
mouth, hypothyroidism, bone impairments (osteoporosis and avascular necrosis), congestive heart failure,
exercise-induced shortness of breath, neurosensory impairments, inability to attend work or school, and poor
overall health. Compared to those receiving no total-body irradiation (TBI), patients treated with TBI-based
conditioning had higher risks of cataracts (odds-ratio [OR] 4.9, 95% confidence interval [CI] 1.5-15.5) and dry
mouth (OR 3.4, 95% CI 1.1-10.4). Females had a greater likelihood of reporting osteoporosis (OR 8.7, 95% CI:
1.8-41.7), congestive heart failure (OR 4.3, 95% CI 1.1-17.2), and abnormal balance, tremor, or weakness (OR
2.4, 95% CI 1.0-5.5). HL and NHL survivors of autologous HCT have a high prevalence of long-term
health-related complications and require continued monitoring for late effects of transplantation.
© 2007 American Society for Blood and Marrow Transplantation
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Autologous hematopoietic cell transplantation (HCT)
s standard therapy for patients with aggressive or
dvanced Hodgkin lymphoma (HL) and non-
odgkin lymphoma (NHL), and can lead to durable
ong-term remissions. Although autologous HCT is
ssociated with low rates of early transplant-related
orbidity and mortality (TRM), the high-dose che-
otherapy and total-body irradiation (TBI) used as cart of conditioning regimens can potentially increase
he risk of late complications of therapy. Lymphoma
urvivors treated with autologous HCT are at a sig-
iﬁcantly higher risk for premature death compared to
he general population [1], and for developing second-
ry solid tumors, leukemia, and myelodysplastic syn-
rome (MDS) [1-6]. However, the incidence and risk
actors for nonmalignant late effects in lymphoma
utologous HCT survivors have not been systemati-
ally investigated.
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N. S. Majhail et al.1154The current analysis from the Bone Marrow
ransplant Survivor Study (BMT-SS) was conducted
o describe the prevalence of, and predictors for, a
road spectrum of medical late complications, func-
ional impairments, and overall general health in sur-
ivors of HL and NHL treated with autologous HCT.
ETHODS
ubjects
The BMT-SS is a collaborative retrospective
ohort study established in 2000 between the City
f Hope National Medical Center and University of
innesota to examine the long-term outcomes of
CT survivors. The present report from the
MT-SS was restricted to subjects who met the fol-
owing eligibility criteria: (1) autologous HCT for HL
r NHL between January 1, 1974, and December 31,
998; (2) age 18 years or older at the time of survey;
nd (3) survival of at least 2 years from HCT. The
nalysis compared late effects of transplant in 276
urvivors of autologous HCT for lymphoma (HL 
2, NHL  184) with a sample of 319 siblings. For
omparison purposes, a group of siblings was enrolled
nto the study by assembling a random sample of study
articipants stratiﬁed on the basis of diagnosis, age,
ex, and ethnic background, asking these participants
o recruit their siblings into the study; and then asking
he siblings to complete the same questionnaire as the
articipants [7]. The comparative evaluations for this
nalysis were not limited to siblings of HL or NHL
articipants, but included siblings of all patients who
ere enrolled in the study and had completed a study
uestionnaire. The study protocol was reviewed and
pproved by the Human Subjects Research Review
ommittee of the participating institutions and all
ubjects provided informed consent prior to partici-
ation in the study.
ata Collection
Participants completed the BMT-SS questionnaire,
255-item survey assessing medical late effects, current
edical conditions, medication use, health status,
ealth behaviors, pregnancy history, demographic
haracteristics, socioeconomic indicators, insurance
overage, and other information. The BMT-SS ques-
ionnaire also asks participants to report impairment
f organ systems, limitations that interfere with daily
unction and the impact of these impairments, and/or
unctional limitations on daily life either at home,
chool, or work. The questionnaire was originally de-
eloped for use by the Childhood Cancer Survivor
tudy [8], and was subsequently modiﬁed to address
opics speciﬁcally related to the HCT survivor popu-
ation. The questionnaire has a yes/no/don’t know
ormat for the majority of questions or a Likert scale e9] or ordinal response to score degree of impairment
r dysfunction. The BMT-SS questionnaire was vali-
ated on a sample of 100 HCT survivors, and the
greement with medical records was excellent (per-
entage agreement adjusted for chance, kappa 0.8)
or musculoskeletal, cardiovascular, pulmonary, and
ndocrine impairments, and moderate (kappa 0.4-0.7)
or second cancers, central nervous system disorders,
nd eye problems [10]. Data on therapeutic exposures
ere abstracted from databases at the 2 participating
nstitutions that prospectively collect HCT-related in-
ormation.
ata Analysis
The prevalence of medical late effects was calcu-
ated by tabulating the yes responses to speciﬁc ques-
ions in the BMT-SS questionnaire. Descriptive sta-
istics including means, medians, standard deviations,
requencies, and ranges were calculated for demo-
raphic variables for the sibling comparison group and
or demographic and treatment variables for partici-
ating and nonparticipating HCT survivors. Two
ample t-test, chi-square test, or Fisher’s exact test, as
ppropriate, were used to compare differences be-
ween survivors and siblings and between lymphoma
ypes among survivors.
Frequencies and percentages were calculated for
edical late effects among siblings and HCT survi-
ors as totals and by lymphoma type (HL versus
HL). The prevalence of each medical late effect,
fter adjusting for age at survey and sex, was compared
etween cases and siblings by calculating odds ratios
nd 95% conﬁdence intervals using generalized esti-
ating equations (GEE) with a binomial distribution
nd a logit link. GEE methods were used in all models
o account for the possible correlation between survi-
ors and siblings from the same family [11]. In an
nalysis limited to survivors only, sex, lymphoma type,
nd the use of TBI were evaluated in relation to the
utcome variables in unconditional logistic regression
odels. These 3 variables were adjusted for each other
n the models with further adjustment for age at trans-
lant and age at survey. Race/ethnicity, stem cell
ource (peripheral blood versus bone marrow), and
nstitution were not identiﬁed as independent predic-
ors of the outcomes, nor did they appreciably alter
he estimates, so they were not included in the ﬁnal
odels. SAS version 9.1 was used for all analyses (SAS
nstitute, Cary, NC).
ESULTS
tudy Participants
A total of 425 patients with HL or NHL met the
ligibility criteria. Of these, 34 (8%) were lost to
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Late Effects in Autologous Transplant for Lymphoma 1155ollow-up and 115 either actively or passively refused
articipation (27%). Participants did not differ from
onparticipants by time since transplant, stem cell
ource, sex, treating institution, or diagnosis. Partici-
ants were more likely to have received TBI as part of
heir conditioning regimen (69.1% versus 59.1%, P 
04), and were older at the time of interview (median
ge 46 [range: 21-73] years versus 42 [range: 18-73]
ears) than nonparticipants.
Characteristics of the study participants are
hown in Table 1. Compared to siblings (median
ge 44 [range: 19-79] years), HL survivors were
ounger (median age 40 [range: 22-63] years),
hereas NHL survivors were older (median age 51
range: 23-73] years) at the time of survey admin-
stration. There were no race/ethnicity differences
etween siblings and NHL survivors; however, HL
urvivors were more likely to be of non-White race/
thnicity compared to siblings (14% versus 7%, P 
04). Both HL and NHL survivors were more likely
o be males.
When compared to NHL, the demographic and
reatment characteristics of HL group were similar,
xcept HL survivors were younger in age both at the
ime of interview and at HCT, and a higher propor-
ion of NHL survivors received TBI as a part of their
onditioning regimen (83% versus 40%, P  .001).
verall, 66% of the patients received peripheral blood
able 1. Demographic and Treatment Characteristics
Siblings
Characteristics N (%)
umber 319 (100) 9
edian age at survey, years 44
Range, years 19-79
ex
Female 203 (64) 4
Male 116 (36) 5
ace/ethnicity
White 296 (93) 7
Non-White 23 (7) 1
edian age at HCT, years NA
Range, years
edian time since HCT, years NA
Range, years
tem cell source
BM NA 2
PBSC NA 5
BM and PBSC NA 1
onditioning regimen
Chemotherapy NA 5
Chemotherapy and TBI NA 3
D indicates standard deviation; HCT, hematopoietic cell transplan
body irradiation; NA, not applicable.
P-value for comparison between siblings and Hodgkin’s lymphom
P-value for comparison between siblings and non-Hodgkin’s lymptem cells (PBSC). irgan-System and Organ Impairments
Table 2 lists the prevalence of selected medical
ate effects in HL and NHL HCT survivors. Com-
ared to siblings, lymphoma survivors (HL and NHL
ombined) were more likely to develop the following
rgan-system and organ impairments: eye impair-
ents (19.2% versus 11.3%, P  .01) including cata-
acts (14.5% versus 3.8%, P  .001); oral health im-
airments (17.8% versus 12.9%, P  .05), including
ry mouth (13.8% versus 0.9%, P  .001) and prob-
ems chewing or swallowing (4.7% versus 1.3%, P 
009); endocrine impairments (22.5% versus 11.3%, P
001) including hypothyroidism (18.8% versus 7.2%, P
.001); bone impairments (7.2% versus 2.5%, P 
007), including osteoporosis (4.3% versus 2.2%,
 .05) and avascular necrosis (3.3% versus 0.3%, P 
04); neurosensory impairments (32.6% versus 20.4%,
 .002), including abnormal sense of taste or smell
12.3% versus 0.6%, P  .001) and abnormal sense of
ouch (20.7% versus 9.7%, P .001); and neuromotor
mpairments (9.8% versus 6.3%, P  .06) including
bnormal balance, tremor, or weakness (9.8% versus
.4%, P  .02). Although lymphoma survivors were
o more likely than siblings to report overall cardio-
ulmonary impairments, they did have a higher risk of
eveloping congestive heart failure (4% versus 0.3%,
 .009), exercise induced shortness of breath (9.8%
ersus 2.5%, P .001), and blood clots in the extrem-
gkin’s Lymphoma Non-Hodgkin’s Lymphoma
P-Value* N (%) P-Value†
) 184 (100)
<.01 51 <.01
23-73
<.01 <.01
81 (44)
103 (56)
.04 .31
166 (90)
18 (10)
44
17-69
6
2-17
34 (18)
128 (70)
22 (12)
31 (17)
153 (83)
BM, bone marrow; PBSC, peripheral blood stem cells; TBI, total
vors.
survivors.Hod
N (%)
2 (100
40
22-63
1 (45)
1 (55)
9 (86)
3 (14)
32
13-54
6
2-17
2 (24)
4 (59)
6 (17)
5 (60)
7 (40)
tation;
a survities (4.7% versus 1.3%, P  .03). There was no
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N. S. Majhail et al.1156igniﬁcant difference between HL and NHL survivors
n the reported prevalence of any medical late effects.
unctional Limitations
The prevalence of functional impairments follow-
ng HCT is detailed in Table 3. Lymphoma survivors
ere more likely than siblings to report that their
urrent health prevented them from attending work
r school (15.6% versus 2.2%). Lymphoma survivors
able 2. Frequency and Percentage of Selected Self-Reported Late Effec
Siblings
Hodgkin L
Surv
Late Effects* N (%) N (%)
umber 319 (100) 92 (100)
ye impairments 36 (11) 11 (12)
Cataracts 12 (4) 8 (9)
Glaucoma 6 (2) 0 (0)
Dry eyes 26 (8) 6 (7)
ral health impairments 41 (13) 11 (12)
Dry mouth 3 (1) 6 (7)
Swollen or bleeding gums 35 (11) 3 (3)
Problems chewing or swallowing 4 (1) 5 (5)
ndocrine impairments 36 (11) 28 (30)
Hypothyroid 23 (7) 26 (28)
Diabetes 10 (3) 3 (3)
Hyperthyroid 5 (2) 2 (2)
Thyroid nodules 8 (3) 0 (0)
one impairments 8 (3) 4 (4)
Osteoporosis 7 (2) 1 (1)
Avascular necrosis 1 (0.3) 3 (3)
ardiopulmonary impairments 83 (26) 17 (19)
Arrhythmia 17 (5) 6 (7)
Congestive heart failure 1 (0.3) 4 (4)
Coronary heart disease 13 (4) 2 (2)
Hypertension 61 (19) 6 (7)
Stroke 1 (0.3) 0 (0)
Exercise induced dyspnea 8 (3) 7 (8)
Pericarditis 0 (0) 1 (1)
Stiff or leaking heart valves 7 (2) 3 (3)
Blood clot in extremities 4 (1) 3 (3)
astrointestinal impairments 29 (9) 8 (9)
Gall stones 16 (5) 0 (0)
Hepatitis 6 (2) 3 (3)
Esophagus stricture or scarring 11 (3) 5 (5)
eurosensory impairments 65 (20) 22 (24)
Blind 5 (2) 0 (0)
Tinnitus or ringing in ears 24 (8) 6 (7)
Complete or partial deafness 8 (3) 2 (2)
Dizziness or vertigo 10 (3) 3 (3)
Abnormal sense of taste or smell 2 (1) 6 (7)
Abnormal sense of touch 31 (10) 15 (16)
euromotor impairments 20 (6) 10 (11)
Paralysis 3 (1) 0 (0)
Balance, tremor or weakness 17 (5) 10 (11)
Within an organ system, subjects could have impairment of more
P-value for comparison between siblings and Hodgkin lymphoma
P-values from generalized estimating equations adjusted for ag
correlation. Fisher’s exact test used for cell sizes 5.
P-value for comparison between siblings and non-Hodgkin lymph
P-value for comparison between siblings and all lymphoma survivere also less likely than siblings to rate their present Nealth as good, very good, or excellent (83.7% versus
4.7%). There was no signiﬁcant difference between
L and NHL survivors in the reported frequencies of
arious functional limitations and overall health.
redictors of Late Effects
Table 4 shows multivariate models with the rela-
ive odds of developing selected late effects and func-
ional limitations based on lymphoma type (HL versus
ma Non-Hodgkin
Lymphoma Survivors All Lymphoma Survivors
ue†‡ N (%) P-Value‡§ N (%) P-Value‡#
184 (100) — 276 (100) —
7 42 (23) .01 53 (19) .01
01 32 (18) <.001 40 (15) <.001
6 0 (0) .96 0 (0) .95
2 13 (7) .64 19 (7) .75
0 38 (21) .01 49 (18) .05
02 32 (17) <.001 38 (14) <.001
4 6 (3) .01 9 (3) .002
2 8 (4) .04 13 (5) .009
01 34 (19) .02 62 (23) <.001
01 26 (14) .0004 52 (19) <.001
9 7 (4) .90 10 (4) .99
6 3 (2) .79 5 (2) .54
6 1 (0.5) .17 1 (0.4) .09
3 16 (9) .007 20 (7) .007
6 11 (6) .04 12 (4) .05
5 6 (3) .06 9 (3) .04
0 43 (23) .06 60 (22) .08
8 12 (7) .95 18 (7) .57
1 7 (4) .02 11 (4) .009
9 8 (4) .88 10 (4) .78
2 10 (5) <.001 16 (6) <.001
9 0 (0) .95 0 (0) .96
05 20 (11) .001 27 (10) <.001
5 3 (2) .95 4 (2) .93
6 2 (1) .27 5 (2) .91
5 10 (5) .05 13 (5) .03
7 17 (9) .59 25 (9) .88
5 9 (5) .77 9 (3) .36
7 6 (3) .57 9 (3) .37
2 3 (2) .08 8 (3) .49
3 68 (37) .001 90 (33) .002
6 1 (0.5) .31 1 (0.4) .21
7 13 (7) .47 19 (7) .74
8 10 (5) .37 12 (4) .38
6 2 (1) .11 5 (2) .37
05 28 (15) <.001 34 (12) <.001
2 42 (23) <.001 57 (21) <.001
2 17 (9) .29 27 (10) .06
5 1 (0.5) .61 1 (0.4) .44
06 17 (9) .13 27 (10) .02
organ.
ors.
rvey and sex and including variance component for intrafamily
rvivors.ts
ympho
ivors
P-Val
—
.1
.0
.9
.8
.9
.0
.0
.0
<.0
<.0
.6
.3
.9
.0
.3
.0
.5
.2
.0
.3
.0
.9
.0
.9
.1
.1
.5
.9
.3
.2
.1
.9
.6
.7
.3
.0
.0
.0
.9
.0
than 1
surviv
e at su
oma suHL), use of TBI as a part of the conditioning reg-
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Late Effects in Autologous Transplant for Lymphoma 1157men, and sex. After adjusting for age at transplanta-
ion and age at survey, females had a higher risk of
eveloping osteoporosis (odds ratio [OR] 8.7, 95%
onﬁdence interval [CI] 1.8-41.7), congestive heart
ailure (OR 4.3, 95% CI 1.1-17.2), and balance im-
airment, tremor, or weakness (OR 2.4, 95% CI 1.0-
.5) compared to males. The relative odds of devel-
ping cataracts and dry mouth were 4.9 times (95%
I 1.5-15.5) and 3.4 times (95% CI 1.1-10.4) higher,
espectively, in survivors who had received TBI as a
art of their conditioning regimen compared to those
ho did not. The type of lymphoma had no impact on
he risk of developing any organ speciﬁc late effects or
unctional limitations.
ISCUSSION
The current study demonstrates that HL and
HL survivors treated with autologous HCT have a
igher prevalence of a wide spectrum of medical late
omplications and functional limitations, and are
ore likely to have a negative perception of their
verall health status compared to their siblings. Fur-
hermore, medical late effects can lead to considerable
unctional impairments as evidenced by a signiﬁcantly
arge proportion of survivors being unable to attend
ork or school because of health problems and grad-
ng their overall health status as only poor to fair.
Nonneoplastic late effects of autologous HCT in
able 3. Frequency and Percentage of Self-Reported Health Status and
Siblings
Hodgkin Lym
SurvivHealth Status and Functional
Impairment N (%) N (%)
umber 319 (100) 92 (100)
eed assistance with activities
of daily living
Yes 1 (0.3) 0 (0.0)
No 318 (99.7) 92 (100.0)
eed assistance with routine
activities
Yes 8 (2.5) 4 (4.3)
No 311 (97.5) 88 (95.7)
ealth prevents work or
school attendance
Yes 7 (2.2) 15 (16.3)
No 312 (97.8) 77 (83.7)
eneral health
Poor/fair 17 (5.3) 16 (17.4)
Good 66 (20.7) 32 (34.8)
Very good 156 (48.9) 31 (33.7)
Excellent 80 (25.1) 13 (14.1)
P-values from generalized estimating equations adjusted for age and
exact test used for cell sizes 5.
P-value for comparison between siblings and Hodgkin lymphoma
P-value for comparison between siblings and non-Hodgkin lymph
P-value for comparison between siblings and all lymphoma survivymphoma survivors have not been well characterized ereviously. Ruiz-Soto et al. [12] studied late toxicity,
eﬁned as adverse events occurring 30 days after
ransplantation, in 158 recipients of autologous HCT
or aggressive NHL. Forty-three patients developed
ate toxicity; common late adverse events included
nfections (19%), neurologic (18%), digestive tract
15%), endocrine (9%), and pulmonary (9%) prob-
ems. However, inclusion of patients in their early
osttransplant period, a short duration of posttrans-
lant follow-up (median followup was 3 years, range:
.2-10 years), and a lack of a control group were
imitations of their study. Lavoie et al. [13] have re-
orted long-term outcomes of 53 HL survivors fol-
owed for at least 10 years or more following autolo-
ous HCT. In this retrospective analysis, common
onmalignant late complications included hypothy-
oidism (38%), hypogonadism (38%), infections
34%), anxiety or depression (13%), and cardiac dis-
ases (9%).
Survivors of HL and NHL treated with chemo-
herapy and/or radiation therapy are at an increased
isk for developing late onset cardiovascular and pul-
onary complications, primarily from toxicity associ-
ted with the use of anthracyclines, bleomycin, and
ediastinal irradiation [14-22]. Lymphoma survivors
n our study reported a higher prevalence of conges-
ive heart failure, exercise-induced shortness of
reath, and blood clots in the extremities. However,
he risk of myocardial infarction, coronary artery dis-
nal Impairments
a Non-Hodgkin
Lymphoma Survivors All Lymphoma Survivors
e*† N (%) P-Value*‡ N (%) P-Value*§
184 (100) 276 (100)
9 .04 .18
4 (2.2) 4 (1.4)
180 (97.8) 272 (98.6)
6 .05 .06
11 (6.0) 15 (5.4)
173 (94.0) 261 (94.6)
01 <.001 <.001
28 (15.2) 43 (15.6)
156 (84.8) 233 (84.4)
01 <.001 <.001
29 (15.8) 45 (16.3)
56 (30.4) 88 (31.9)
65 (35.3) 96 (34.8)
34 (18.5) 47 (17.0)
d including variance component for intrafamily correlation. Fisher’s
ors.
rvivors.Functio
phom
ors
P-Valu
.5
.3
<.0
<.0
sex an
surviv
oma suase, angina, valvular heart disease, stroke, and lung
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N. S. Majhail et al.1158brosis was comparable to that of siblings. This low
revalence of speciﬁc cardiopulmonary outcomes
ould result from the relatively young age of our study
articipants, both subjects and siblings, and the rela-
ively short duration of follow-up after transplanta-
ion.
Female lymphoma survivors were at an increased
isk of developing congestive heart failure and osteo-
orosis. In a previous study, we have observed female
utologous HCT recipients to have a 4-fold higher
isk of late death from cardiac complications com-
ared to age- and sex-matched general population
ontrols [1]. Although previous studies have not dem-
nstrated a sex preference in the risk of osteoporosis
fter autologous HCT [23,24], ovarian ablation sec-
ndary to high-dose chemotherapy and TBI could
ossibly explain the increased risk of this late effect in
emales. Nonetheless, modiﬁable risk factors for car-
iac disease and osteoporosis should be identiﬁed
arly and appropriately managed in lymphoma survi-
ors of autologous HCT, especially females.
Compared to siblings, survivors in our study had a
reater likelihood of having functional impairments
nd an adverse perception of their overall health sta-
us. Although no other study has speciﬁcally charac-
erized functional limitations in lymphoma survivors,
imilar observations have been described previously in
able 4. Relative Odds of Having Selected Late Effects Based on Type
f Lymphoma, Use of Total-Body Irradiation (TBI) in Conditioning
egimen, and Sex
Odds
Ratio 95% CI P-Value
ataracts
Hodgkin lymphoma 1.1 0.4-3.0 .79
TBI 4.9 1.5-15.5 .007
Female 1.1 0.6-2.3 .72
ry mouth
Hodgkin lymphoma 0.5 0.2-1.4 .17
TBI 3.4 1.1-10.4 .03
Female 1.5 0.7-3.1 .26
steoporosis
Hodgkin lymphoma 0.3 0.03-2.9 .31
TBI 1.6 0.3-8.4 .57
Female 8.7 1.8-41.7 .007
ongestive heart failure
Hodgkin lymphoma 2.4 0.5-11.8 .27
TBI 0.8 0.2-3.2 .77
Female 4.3 1.1-17.2 .04
alance impairment, tremor,
or weakness
Hodgkin lymphoma 1.1 0.4-3.1 .83
TBI 0.6 0.3-1.6 .32
Female 2.4 1.0-5.5 .04
or each variable, odds ratios were adjusted for the other variables
with further adjustment for age at transplantation and age at
survey.
I indicates conﬁdence interval.tudies that have included recipients of autologous CCT for hematologic disorders [25-27]. In a self-
eported survey administered serially over the ﬁrst 2
ears posttransplant by Lee et al. [26], a large propor-
ion of autologous HCT survivors were observed to
ave persistent functional restrictions over time.
Thirty-ﬁve percent of the eligible cohort did not
articipate in this study, and the participants were
lder at study participation than the nonparticipants;
his could be a potential source of bias for our study.
owever, comparison with the siblings was age ad-
usted. Furthermore, the results of this study are based
n self-reported medical information and could pos-
ibly result in misclassiﬁcation of the outcomes of
nterest. To overcome this limitation, a validation
tudy was conducted on HCT recipients at City of
ope National Medical Center, and demonstrated
hat self-report of complications using the BMT-SS
uestionnaire has good to excellent agreement with
ata abstracted from medical records [10]. Addition-
lly, the sibling comparison group also self-reported
ata, hence eliminating any systematic differences in
ias between the 2 comparison groups. There is also a
otential for overdetection bias in our study, with
ore vigilance for speciﬁc late effects in HCT survi-
ors compared to healthy sibling controls. Finally, we
id not account for other known risk factors for sev-
ral outcomes, such as family history, smoking history,
ctivity level, and pretransplant therapy, in our anal-
ses. These pretransplant exposures, especially prior
hemotherapy and radiation therapy, can indepen-
ently increase the risk of developing speciﬁc late
omplications in lymphoma survivors. However, the
isk of these late complications may be further com-
ounded by the high-dose chemotherapy and TBI
outinely used as a part of the conditioning regimen
or autologous HCT.
These limitations notwithstanding, our study
omprehensively describes the magnitude of risk of
edical late effects and functional limitations, and
valuates risk factors for these outcomes in HL and
HL survivors of autologous HCT. This study dem-
nstrates that long-term survivors are at increased risk
f late effects that results in functional limitations and
herefore provides the justiﬁcation for continued
onitoring and surveillance of this population using
ublished guidelines [28].
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